Risk-taking in the era of highly active antiretroviral therapy John P. PhairDavid G. Ostrow Invited Commentary Pages: 101 - 102
Antibiotic use and the risk of hemolytic-uremic syndrome in Escherichia coli O157:H7 infections in children David A. Bobak Clinical Trials Report Pages: 107 - 108
Management and prevention of Clostridium difficile-associated diarrhea William P. Ciesla JrDavid A. Bobak OriginalPaper Pages: 109 - 115
Campylobacter enteritis and the Guillain-Barré syndrome Irving Nachamkin OriginalPaper Pages: 116 - 122
Recent advances in the management of infections in liver transplant recipients Nina Singh OriginalPaper Pages: 123 - 130
Current options for the therapy of chronic hepatitis B infection Suzane Kioko Ono-NitaNaoya KatoMasao Omata OriginalPaper Pages: 137 - 142
Ceftriaxone and penicillin G as treatment for neurosyphilis in HIV-infected individuals Anne Rompalo Clinical Trials Report Pages: 145 - 145
Impact of new sexually transmitted disease diagnostics on clinical practice and public health policy Jeanne M. Marrazzo OriginalPaper Pages: 147 - 151
Role of vaginal flora as a barrier to HIV acquisition Jane R. Schwebke OriginalPaper Pages: 152 - 155
Quinolone resistance in Neisseria gonorrhoeae Janine R. TompkinsJonathan M. Zenilman OriginalPaper Pages: 156 - 161
Efforts to control sexually transmitted diseases as a means to limit HIV transmission: Pros and cons Gina DallabettaMadaline Feinberg OriginalPaper Pages: 162 - 168
Will new human papillomavirus diagnostics improve cervical cancer control efforts? Shalini L. KulasingamLaura A. Koutsky OriginalPaper Pages: 169 - 180
Metabolic complications of HIV and AIDS Alison StrawfordMarc K. Hellerstein OriginalPaper Pages: 183 - 192